SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy to soon supply anti-ulcer drug Nexium’s low-cost version

13 May 2011 Evaluate

Ranbaxy Laboratories expects to start supplying a low-cost version of anti-ulcer drug, sold under the brand Nexium by AstraZeneca to the British drugmaker, towards the end of 2011. The drugmaker had entered into an agreement three years ago to supply a cheap version of the drug to Astra-Zeneca starting May 2010, that could fetch $40-50 million in annual revenues for Ranbaxy. The supply has been delayed due to pending approvals from the American drug regulator as the medicine is to be sold by AstraZeneca in the US.crackcrack

Peers
Company Name CMP
Sun Pharma Inds. 1665.70
Dr. Reddys Lab 1220.00
Cipla 1232.60
Zydus Lifesciences 928.05
Lupin 2305.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×